Integra LifeSciences (NASDAQ:IART) Sets New 12-Month High – Should You Buy?

Integra LifeSciences Holdings Corporation (NASDAQ:IART) hit a new 52-week high during trading on Monday . The stock traded as high as $20.32 and last traded at $20.27, with a volume of 88953 shares. The stock had previously closed at $19.79.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on IART shares. Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research note on Thursday, June 18th. Wall Street Zen cut Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 18th. BMO Capital Markets assumed coverage on Integra LifeSciences in a report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price objective on the stock. Finally, Citigroup restated a “neutral” rating and issued a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $18.33.

Integra LifeSciences Trading Up 1.6%

The stock has a market cap of $1.56 billion, a PE ratio of -3.10, a price-to-earnings-growth ratio of 1.37 and a beta of 1.22. The company’s 50-day moving average price is $17.39 and its 200 day moving average price is $13.31. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The company had revenue of $391.92 million during the quarter, compared to analysts’ expectations of $381.81 million. During the same quarter last year, the firm earned $0.41 earnings per share. The firm’s quarterly revenue was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, sell-side analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

A number of hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Integra LifeSciences by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after purchasing an additional 1,975 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Integra LifeSciences in the first quarter valued at $277,000. Goldman Sachs Group Inc. raised its holdings in shares of Integra LifeSciences by 2.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock valued at $36,515,000 after buying an additional 35,790 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Integra LifeSciences by 23.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock worth $5,373,000 after acquiring an additional 45,693 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in Integra LifeSciences during the 2nd quarter worth about $491,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.